News
The day at a glance · 4 min read
Mood · Cautious
+15
Sentiment, −100 to +100
UNH Q3 Revenue
$112.7BFlat YoY
UNH Q3 EPS Beat
$4.69+13.3%
J&J Oncology Target
$50B+By 2030
Key driverUnitedHealth's Q3 beat and margin recovery offset by Johnson & Johnson medtech weakness and broader healthcare sector pressure.
Daily briefHealthcare· Money365.Market AI ·

UnitedHealth Beats Q3 Estimates; J&J Signals M&A Appetite

UNH delivers strong quarter with margin recovery while J&J targets oncology deals; oncology spending set to exceed $400 billion by 2028.

Healthcare Market Overview

Neutral

Global Cancer Spending 2028

$400B+From $252B in 2024
01UNH
UnitedHealth Group ($UNH) reported Q3 2026 results that topped revenue expectations with sales of $112.7 billion, though flat year-over-year, while non-GAAP profit of $4.69 per share came in 13.3% above analysts' consensus estimates. The health insurer remains Mizuho Securities' top pick in the U.S. healthcare sector following the stronger-than-expected results that reinforced confidence in the company's recovery in profitability. CFO Wayne DeVeydt called the lower end of the company's 13% to 16% long-term earnings growth target a "reasonable starting point" for 2027.
02UNH
UnitedHealth ($UNH) stock is outpacing the S&P 500 in 2026 and is on track for its best year since the pandemic, with analysts suggesting Wall Street may be underestimating 2027 upside.
03JNJ▼ -5.73%
Johnson & Johnson ($JNJ) remains open to strategic acquisitions and has set a target of more than $50 billion in oncology sales by 2030, with funds raising their bets as the company stays "on the lookout" for deals. The company faced pressure as its selloff exposed medtech strain that outweighed pharma strength, illustrating how device weakness can overshadow pharmaceutical performance in diversified healthcare stocks. Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028 according to the IQVIA Institute, with the United States accounting for roughly 46% of the total.

Big Pharma & Biotech

Bullish

Pfizer-Enodia Deal

$500M

BMY Net Income

$7.1B+Recovery

LLY Net Income

$20.6B+More than doubled

Oncology Launch Activity

+40%+2020-2024 vs prior 5 years
PFELLYBMY
01PFE
Pfizer ($PFE) entered a partnership with Enodia Therapeutics in a $500m drug deal under which Enodia will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets. The collaboration adds to Pfizer's strategy of acquiring drugs and cutting costs to bridge the patent cliff gap the company expects in 2028.
02LLY
Eli Lilly ($LLY) recently reported exploratory Phase 3b data from the TOGETHER-PsO trial showing that combining Taltz with Zepbound in adults with moderate-to-severe plaque psoriasis and obesity altered far more immune and metabolic biomarkers than Taltz alone, with broader responses emerging as early as Week 12. The findings highlight a potential immunometabolic link between psoriasis and obesity, suggesting the company could unlock new treatment approaches by pairing its immunology and metabolic franchises.
03BMY▼ -1.58%
Bristol Myers Squibb ($BMY) recovered to $7.1B in net income while Eli Lilly ($LLY) more than doubled profits to $20.6B, presenting a stark contrast in momentum that reshapes the value-versus-growth debate among large-cap pharma stocks.
04
About 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years as colorectal and pancreatic cancers moved up the research agenda.

MedTech & Devices

Bullish

Single-Use Assemblies CAGR

22.8%+2026-2030

3D Cell Culture CAGR

19.9%+2026-2030
01ABT
Abbott Laboratories ($ABT) has been identified as a leading group advancing closed-loop neurostimulation in bioelectronic medicine devices, with the company highlighted for closed-loop neurostimulation systems that interact with neural signals to modulate treatment in real time. This focus on bioelectronic medicine complements Abbott's existing work in cardiac and diabetes devices targeting chronic and neurological conditions. The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan according to Longleaf Partners Fund's Q3 2026 portfolio review.
02TMO
The global single-use assemblies market is experiencing rapid growth with a 22.8% CAGR as companies including Thermo Fisher ($TMO), Danaher, Sartorius, Merck ($MRK), and Avantor scale modular bioprocessing systems that cut cleaning and contamination costs while speeding fill-finish operations. The global 3D cell culture technologies market is capitalizing on a 19.9% CAGR as companies scale organoids and high-throughput platforms that maximize limited cells and localize production.

Diagnostics & Research Tools

Bullish

Metabolomics Market CAGR

17.3%+2026-2030

Metabolomics Market Size

$4.17B+Base year
01TMO
The global metabolomics market is experiencing rapid expansion with a 17.3% CAGR driven by advances in biomarker discovery, personalized medicine, cancer research and analytical technologies, with the market growing from $4.17 billion as companies including Metabolon, Bruker, Agilent, Thermo Fisher ($TMO) and Waters accelerate AI diagnostics capabilities. Players in the space are expanding products, services, market share, segments, trends, opportunities and regional presence to capitalize on the growing demand for metabolomic profiling in clinical and research settings.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy